Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 202.50

-2.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: WTDEC who wrote (21379)	5/25/1998 5:07:00 PM
From: Flagrante Delictu	Read Replies (1) of 32384

Walter, The SRGN EGF Fusion Protein is currently in Phase I/II clinical trials for non-small cell lung cancer. It is also in pre-clinical development in collaboration with U.S. Surgical Corporation for restinosis following angioplasty. Herceptin has completed Phase III trials. Yet Herceptin only works in certain patients and is not a cure, but it opens the door for the development of better drugs to do the job better. Coulter's antibody drug for cancer spikes its' tumor seeking antibody with a radioactive drug. IDEC's Rituxan uses an antibody which seeks out certain cancer cells to target the treatment with pinpoint precision. SRGN has licensed its'technology to DiagnoCure of Quebec to provide DiagnoCure's Nanovectors with an effective method of targeting cells for purposes such as gene therapy. DiagnoCure not only signed a licensing agreement this Feb. with SRGN but also a collaborative research & consultation agreement with Dr. John Murphy, one of SRGN's founders & a world authority in the field of protein engineering. Sounds like this guy could be quite an asset to a company that could fund his ideas. Based on what I have read of DiagnoCure, LGND should look at buying them also. On 7/31/97 SRGN got $5 million from U.S.Surgical for the option on its' technology for restinosis in angioplasty patients. U.S. Surgical has 15 months to decide whether to pick up the option at a cost of another $5 million for worldwide rights. USS has agreed to fund trials associated with the development of EGF Fusion Protein for restinosis. If the option is exercised, milestone payments to SRGN (LGND) by USS could amount to $22.5 million in addition to royalties upon commercial sales by USS.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next